Gastrointestinal Stromal Tumor (GIST): A Remarkable Case Report and Literature Review

Bassey Enodien ¹, Dana Hendie ², Tobias Müller ¹, Stephanie Taha-Mehlitz ³, Daniel M. Frey ¹, Anas Taha ¹

¹. Department of Surgery, GZO Hospital, Wetzikon, CHE ². Department of Surgery, College of Medicine, Sulaiman Al Rajhi University, Albukairyah, SAU ³. Clarunis, Department of Visceral Surgery, University Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Basel, CHE

Corresponding author: Anas Taha, anas.taha@unibas.ch

Abstract

Gastrointestinal stromal tumor (GIST) makes up less than 1% of all gastrointestinal tumors, but it is the most common mesenchymal tumor of the digestive system. It is commonly found in the stomach and the small intestine and rarely seen in the colon and the esophagus. Additionally, sigmoid GIST is quite rare since colorectal GIST often occurs in the rectum. A total of 21 patients (including the study case) were looked at for this study, of which 14 (66.6%) were males and seven (33.3%) were females. We focused on GIST and conducted an online search and systematic analysis of all case presentations.

Categories: General Surgery
Keywords: review, colorectal gist, gastrointestinal stromal tumor (gist), perforation, gist

Introduction

Gastrointestinal stromal tumor (GIST) is one of the most prevalent mesenchymal tumors of the digestive tract despite constituting less than 1% of all gastrointestinal tumors. Historically, it was thought to originate from smooth muscle and misclassified as leiomyoma, leiomyoblastoma, and leiomyosarcoma [1]. However, due to modern advancements in molecular technique, it was discovered that GIST originates from the interstitial cells of Cajal or a precursor cell [2]. It was also uncovered that it was caused most importantly by an oncogenic mutation in the KIT gene, which is responsible for the regulation of tyrosine kinase [3]. Most GISTs usually occur in the stomach followed by the small intestine and rarely in the colon and esophagus. Furthermore, colorectal GIST is usually in the rectum, so sigmoid GIST is rather uncommon [4].

Case Presentation

A 74-year-old male with a background of chronic obstructive pulmonary disease presented to the emergency department with a sudden onset of severe abdominal pain located in the lower abdomen. Moreover, despite normal laboratory results, the patient’s pain did not abate. An abdominal computed tomography (CT) scan was performed, and it illustrated a mid to lower intestinal perforation, suspected to be from either the sigmoid or the small bowel. Moreover, a diagnostic laparoscopy was done. The examination revealed diffuse peritonitis, fecal soiling of the entire abdomen, a 1.5 cm sigmoid colon perforation, and what appeared to be a small tumor close to the site, as can be seen in Figure 1.
FIGURE 1: A laparoscopic view that reveals widespread peritonitis and widespread feces.

A) A 1.5 cm sigmoid colon perforation. B) Little tumor (arrow) adjacent to the perforation

Foremost, the removal of fecal material and the irrigation of the entire abdomen were initiated. Thereafter, laparoscopic partial sigmoid resection, i.e., Hartmann procedure, was done, and the tumor was then sent to for histological examination. The tumor is shown to express cluster of differentiation (CD) 117 and discovered on gastrointestinal stromal tumor protein 1 (DOG-1) confirming the diagnosis of a GIST, measuring at 0.7 cm with a low mitotic rate. There was no evidence of lymphatic or perineural sheath infiltration. The tumor’s tumor-node-metastasis (TNM) classification was pT1 L0 V0 Pn0 R0. Microscopically, the tumor had a spindle-like morphology with no necrosis nor high-grade atypia. It is also pertinent to note that the patient has experienced a myriad of complications following surgery including sigmoid stump insufficiency, multiple abscesses, urinary retention, postoperative ileus, intermittent tachycardic atrial fibrillation, and recurrent pleural effusion. The patient’s complications were treated over a period of several weeks, and he was later discharged. It was determined that the patient required follow-up examinations every 6-12 months. However, the patient refused chemotherapy, so annual CT scans are done regularly.

Methods

We searched the internet for data on GIST and systematically analyzed all case reports from September 16, 2022, to October 6, 2022. Using the search phrases "Gastrointestinal stromal tumour case report," all studies were located on National Center for Biotechnology Information (NCBI)-PubMed (www.pubmed.gov) and Embase (www.embase.com). The inclusion criteria were determined to be patients suffering from GIST, patients of both sexes, patients of various ages, patients of various body weights, and patients of various particular medically significant habits. Furthermore, the exclusion criteria were patients with comorbidities that could raise their risk for adverse events or affect the study’s findings, patients with terminal illnesses, patients with more than one tumor, or patients with a tumor other than the GIST, as well as patients who are
likely to be lost to follow-up, missed data collection interviews, or gave inaccurate information. We looked at all studies applicable in English (or those having relevant English-language abstracts). The search results were as follows: There were 341 articles (not duplicates), of which 274 papers were disregarded because they did not primarily address GIST in their research title or abstract. Additionally, 47 publications were disregarded throughout the data extraction process after applying the inclusion and exclusion criteria. The other 20 papers were all then added to this study, and they were all carefully evaluated and assessed, as seen in Figure 2.

![FIGURE 2: PRISMA diagram depicting the flow of information across the various phases of a systematic review.](image)

NCBI, National Center for Biotechnology Information; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses

### Result

According to our research of the literature, a total of 21 patients (including the study case) were investigated, of which 14 (66.6%) were males and seven (33.3%) were females. Their ages varied from 30 to 85 years, with a mean age of 64.05. The vast majority of patients (61.9%) were above the age of 60. The majority of cases demonstrate that the tumor had spindle cells with a high rate of mitosis. Additionally, immunocytochemistry shows that the majority of patients have a strong positivity to certain antibodies such as CD117, DOG-1, CD34, and vimentin being expressed, as seen in Table 1.

<table>
<thead>
<tr>
<th>Article</th>
<th>Age/years</th>
<th>Gender</th>
<th>Complaint</th>
<th>Site</th>
<th>Antibodies expressed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present case</td>
<td>74 years</td>
<td>Male</td>
<td>Presented to the emergency department (ED) with severe abdominal pain</td>
<td>Sigmoid colon</td>
<td>CD117 (+) and DOG-1 (+)</td>
</tr>
<tr>
<td>Name et al., 2021</td>
<td>71 years</td>
<td>Male</td>
<td>Reported to the emergency room with a 38-hour history of intermittent hematochezia and diffuse abdominal pain</td>
<td>Small intestine (third jejunal segment)</td>
<td>CD117 (+), DOG-1 (+), SDHB (+), desmin (+), actin (+), CD34 (-), and S-100 (-)</td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Yang et al., 2022</td>
<td>59 years</td>
<td>Male</td>
<td>The patient’s symptoms are consistent with incomplete obstruction: the patient felt unclean and noticed a shift in bowel habits with more frequent stools with a decrease in single stool volume</td>
<td>Rectum</td>
<td>CD117 (+), DOG-1 (+), CD34 (+), and Ki67 (+)</td>
</tr>
<tr>
<td>Tezcan and Koç, 2011</td>
<td>83 years</td>
<td>Male</td>
<td>Complaint of constipation and then one year later complaint of pain in the right hip</td>
<td>Rectum</td>
<td>CD117 (+), CD34 (+), S-100 (-), SMA (-), and desmin (-)</td>
</tr>
<tr>
<td>Sugimoto et al., 2013</td>
<td>52 years</td>
<td>Male</td>
<td>Complaint of anorexia and physical exhaustion</td>
<td>Upper stomach</td>
<td>CD117 (+), CD34 (+), S-100 (-), SMA (-), and desmin (-)</td>
</tr>
<tr>
<td>Manxhuka-Kerliu et al., 2014</td>
<td>30 years</td>
<td>Female</td>
<td>Presented with nausea, vomiting, and abdominal pain</td>
<td>Small intestine</td>
<td>CD117 (+), CD34 (+), vimentin (+), actin (+ focally), desmin (-), and S-100 (-)</td>
</tr>
<tr>
<td>Cheng et al., 2019</td>
<td>78 years</td>
<td>Female</td>
<td>Referred to the hospital with 10 days of ongoing vaginal bleeding and difficulty urinating</td>
<td>Cervical or rectal mass with rectovaginal invasion</td>
<td>CD117 (+), DOG-1 (+), H-caldesmon (+), actin and SMA (-), p40 (-), and S-100 (-)</td>
</tr>
<tr>
<td>Liu et al., 2018</td>
<td>72 years</td>
<td>Male</td>
<td>Complaint of upper abdominal pain for one month with regurgitation and weight loss</td>
<td>Gastric fundus</td>
<td>CD117 (+), vimentin (+), CD34 (+), S-100 (+), SMA (+), WT1 (-), Ki67 (-), and BCL-2 (-)</td>
</tr>
<tr>
<td>Wang et al., 2017</td>
<td>74 years</td>
<td>Female</td>
<td>Hospitalized as a result of worsening abdominal pain for two days with history or three months of abdominal pain and distention</td>
<td>Gastric fundus</td>
<td>CD117 (+), H-caldesmon (+), DOG-1 (+), SMA (weak +), CD34 (-), S-100 (-), desmin (-), and NSE (-)</td>
</tr>
<tr>
<td>Lech et al., 2015</td>
<td>52 years</td>
<td>Male</td>
<td>Reported losing about 5 kg in the last two weeks along with frequent heartburn and overall malaise</td>
<td>Posterior gastric wall</td>
<td>CKAE1 (+), vimentin (+), CD117 (-/ +), CD34 (-), CD30 (-), AE3 (-), S-100 (-), H-caldesmon (-), actin (-), MCT (-), and fat (+)</td>
</tr>
<tr>
<td>Xu et al., 2015</td>
<td>53 years</td>
<td>Male</td>
<td>History of intermittent abdominal pain and bloating without any constitutional symptoms</td>
<td>Mesentery of the small intestine</td>
<td>CD117 (c-KIT) (+), vimentin (+), CD34 (partial +), CD68 (partial +), DOG-1 (-), lysozyme (-), HMB45 (-), S-100 (-), and cytokerin (-)</td>
</tr>
<tr>
<td>Yuval et al., 2014</td>
<td>64 years</td>
<td>Female</td>
<td>Presented with melena and syncope to the emergency department (ED) (hypovolemia)</td>
<td>Jejunum</td>
<td>CD117 (+)</td>
</tr>
<tr>
<td>Misawa et al., 2014</td>
<td>70 years</td>
<td>Male</td>
<td>Presented with a fever and abdominal pain</td>
<td>Jejunum</td>
<td>CD117 (+) and CD34 (+)</td>
</tr>
<tr>
<td>Ma et al., 2017</td>
<td>56 years</td>
<td>Male</td>
<td>Presented with a 24-hour melena history</td>
<td>Jejunum</td>
<td>CD117 (+), CD34 (+), and DOG-1 (+)</td>
</tr>
<tr>
<td>Skipworth et al., 2014</td>
<td>51 years</td>
<td>Female</td>
<td>A one-day history of acute, sudden-onset epigastric pain</td>
<td>Gastric antrum</td>
<td>CD117 (+) and CD117 (-)</td>
</tr>
<tr>
<td>Niazi et al., 2014</td>
<td>55 years</td>
<td>Female</td>
<td>Presented with a vague abdominal pain; various investigations were negative. She experienced acute abdominal pain a year later</td>
<td>Rectosigmoidal mass</td>
<td>CD117 (+), CD34 (+), SMA (-), S-100 (-), ALK (-), beta-catenin (-), AE1/3 (-), and desmin (equivocal)</td>
</tr>
<tr>
<td>Iusco et al., 2023</td>
<td>76 years</td>
<td></td>
<td></td>
<td></td>
<td>CD117 (+), CD34 (weak+)</td>
</tr>
</tbody>
</table>
TABLE 1: The clinical features and an overview of the case reports presenting gastrointestinal stromal tumor (GIST).

<table>
<thead>
<tr>
<th>Authors</th>
<th>Age</th>
<th>Gender</th>
<th>Presentation</th>
<th>Location</th>
<th>Immunohistochemical Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Đokić et al., 2019 [21]</td>
<td>62 years old</td>
<td>Male</td>
<td>Presented to the emergency room with severe epigastric pain that persisted for days and black stool lasting for a week with vomiting, inappetence, and weight loss</td>
<td>Lesser curvature of the gastric body</td>
<td>CD117 (+) and DOG-1 (+)</td>
</tr>
<tr>
<td>Sahin et al., 2014 [22]</td>
<td>62 years old</td>
<td>Male</td>
<td>Referred to the hospital two years prior with abdominal pain, nausea, and vomiting</td>
<td>Gastric antrum</td>
<td>CD117 (+) and CD34 (+)</td>
</tr>
<tr>
<td>Zhang et al., 2022 [23]</td>
<td>85 years old</td>
<td>Male</td>
<td>Presented to the hospital after experiencing frequent dark stools for 1.5 years</td>
<td>Gastric antrum</td>
<td>CD117 (weak +), CD34 (+), DOG-1 (+), SDHB (+), and CKP (-)</td>
</tr>
<tr>
<td>Zhou et al., 2012 [24]</td>
<td>66 years old</td>
<td>Female</td>
<td>Presented with an aggravated abdominal ache that had been persistent for a year and was mostly accompanied by distension, eructation, epigastric fullness, decrease of food intake, and early satiety</td>
<td>Lesser curvature of the stomach</td>
<td>CD117 (+), CD34 (+), DOG-1 (+), Ki67 (+), and S-100 (-)</td>
</tr>
</tbody>
</table>

These individuals’ medical histories were examined, and it was discovered that the majority of them complained of vague symptoms that may have misled the diagnosis. Complaints vary from constipation, exhaustion, nausea, and vomiting and can even progress to acute severe pain, shock, or other emergencies. The average tumor size in these cases is 8.39 cm. The data that was collected also revealed the tumor’s site, as seen in Figure 3.
FIGURE 3: The percentage of the research population's tumor sites.

Discussion

Despite GIST being the most common gastrointestinal mesenchymal tumor, its precise and exact global incidence is still under consideration due to the absence of a complete definition and classification. However, it is estimated that 10-20 million people are afflicted by it [1]. With patients as young as 10 and as old as 100, the age distribution can vary greatly; the average age was found to be in the mid-60s. The gender distribution is equal. It is generally believed that the stomach (55.6%) and small intestine (31.8%) are the most prevalent sites for GIST, with the colon (6.0%) and esophagus (0.7%) being uncommon sites [25]. In regard to colonic GIST specifically, it is believed that the most common location is the sigmoid colon followed by the transverse colon, the descending colon, the ascending colon, and then the cecum [26].

Symptoms that lead to the diagnosis of a GIST are often vague, such as abdominal pain and bloating [3]. More specifically, gastric and small intestinal tumors cause ambiguous symptoms; occasionally, it presents as upper gastrointestinal tract bleeding and pain [4]. On the other side, bleeding and blockage may be observed with colorectal GIST. Additional early signs include pelvic and rectal pain, constipation, blockage, or a tumor on physical examination of the rectal cavity. Insidious signs of colorectal GIST include anemia, weight loss, and urinary symptoms including diminished stream strength or hesitation [27]. GIST can also be completely asymptomatic and found only incidentally during scans or physical examination. A small fraction of GIST can also be malignant [4]. GIST stretches widely along the array of malignant protentional at all locations of occurrence. Tumors that exhibit low mitotic rate of less than five mitoses per 50 high-power fields (HPF) are often benign, but there is definitely a percentage among them that metastasize [28]. However, a combination of small tumor that is less than 5 cm with a low mitotic rate is relatively enough to designate a tumor as low risk [4]. Moreover, large tumors of more than 5 cm in size and more than five mitoses per 50 HPF are considered of higher risk. High-grade malignant GIST, which are more than 50 mitoses per 50 HPF, can metastasize commonly intra-abdominally or to the liver. However, it is critical to emphasize that no lesion can be absolutely regarded as benign regardless of size and mitotic rate.

In regard to anatomical location, there is no consensus if it is a reliable predictor of malignant behavior [28]. GIST often appears grossly as an exophytic growth, appearing as a mass. Moreover, it is well-defined with a
pseudo capsule and a smooth, gray, and white tint. Rarely, necrosis, bleeding, and cystic degeneration may be present [29]. Microscopically, GIST can appear as either one of the following groups: spindle cell (70%), epithelioid (20%), or mixed type (10%) [28]. Moreover, it was observed that anorectal tumors mostly fall in the spindle cell group, while surprisingly, colonic GISTs usually fall in the epithelioid category [27]. GIST is usually diagnosed by a myriad of antibodies including CD54, CD117, and DOG-1 [2]. The golden standard treatment of GIST regardless of location is surgical resection; usually, en bloc resection is done as GIST attaches to the surrounding organs and is very fragile [29]. However, surgery does not negate the risk of recurrence, which can be as high as 50%. Various chemotherapies were investigated due to this high recurrence rate, which led eventually to the discovery of imatinib, due to its natural resistance for conventional chemotherapy. This drug can be utilized after surgery in high-risk patients, in cases of metastasis or an unresectable tumor, as well as neoadjuvant therapy [27]. Imatinib can be substituted with other medications such as sunitinib and regorafenib. With varying degrees of success, newer therapeutics are still being researched, including endoscopic ultrasound-guided alcohol injection for GIST and several immunotherapies such nivolumab and ipilimumab [30]. Patients must be monitored for the rest of their lives.

Conclusions
GIST is the most frequent gastrointestinal mesenchymal tumor; however, due to the lack of a comprehensive definition and classification, its true global incidence is still being debated. According to the literature, in our analysis of case reports, we have found that most GISTs are located in the stomach and are spindle-shaped. Moreover, most of these tumors were over 5 cm in size and have a high mitotic rate. GIST frequently exhibits symptoms, but the majority of these symptoms are vague and might mislead the diagnosis. This can result in sudden severe pain, shock, and other symptoms such as constipation, tiredness, nausea, and vomiting. Resection is the gold standard treatment for GIST and is typically followed by chemotherapy. Also, patients typically need lifelong follow-up.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
Bassey Enodien and Dana Hendle are the co-first authors. Anas Taha and Daniel M. Frey are the co-last authors.

References